INVESTOR RELATIONS

Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Recent News
Upcoming Events
Wednesday, April 5, 2017 3:40 p.m. ET
16th Annual Needham Healthcare Conference
 
Stock Information
NASDAQ  |  NTLA (Common Stock)
$13.45 + 0.27
Stock chart for: NTLA.O.  Currently trading at $13.45 with a 52 week high of $30.40 and a 52 week low of $10.83.
03/28/17 11:27 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
 
IR Contacts

John Graziano
Trout Group, LLC
646-378-2942

Chad Rubin
Trout Group, LLC
646-378-2947